Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy
Trial status:Recruitment Complete
Trial ID:
BNT327-01
NCT ID:
EudraCT ID:
N/A
Sponsor:
The sponsor of a clinical trial is the company, institution or individual that takes responsibility for initiating, managing, and/or financing a clinical investigation. BioNTech collaborates with other pharmaceutical companies or institutions (collaborators) to develop certain new medicines. In particular cases BioNTech's collaborators are leading specific clinical trials and are acting as sponsors accordingly.
BioNTech SE
Recruitment Complete
Trial Details
This is a Phase II, multi-site, open-label, parallel group study in participants with untreated extended-stage small-cell lung cancer (ES-SCLC) (Cohort 1) or small-cell lung cancer (SCLC) which has progressed on first- or second-line treatment (Cohort 2 and Cohort 3). This study will assess the safety, efficacy, and pharmacokinetics (PK) of BNT327.
Medical Condition
Trial Drug
See more
Phase
Phase 2
Type
Interventional
Estimated Enrolment
110
Estimated Trial Date
Aug 2024 - Mar 2025
Trial Participant Requirements
Age
18+ years
Sex
Female & Male
Healthy Volunteers
No
Trial Locations
Location
Status
Location
Alaska Oncology and Hematology, LLC
Anchorage, Alaska, United States, 99508
Status
Location
Valkyrie Clinical Trials
Los Angeles, California, United States, 90067
Status
Location
Clermont Oncology Center
Clermont, Florida, United States, 34711
Status
Location
Hematology Oncology Associates of Treasure Coast
Port Saint Lucie, Florida, United States, 34952
Status
Location
Tallahassee Memorial Physician Partners - Cancer & Hematology Specialists
Tallahassee, Florida, United States, 32308
Status
Location
Carle Foundation Hospital d/b/a Carle Cancer Center
Urbana, Illinois, United States, 61801
Status